Emilio Bria

Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Roberto Ferrara, Laura Mezquita, Matthieu Texier et al. · JAMA Oncology · 2018 · 719 citations · Full text

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

François‐Clément Bidard, Virginia Kaklamani, Patrick Neven et al. · Journal of Clinical Oncology · 2022 · 626 citations · Full text

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

Marina Chiara Garassino, Jennifer G. Whisenant, Li‐Ching Huang et al. · The Lancet Oncology · 2020 · 621 citations · Full text

Virus Epidemiology, Medicine, Covid-19 Pandemic +12

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

S. Loibl, Ian J. Majewski, Valentina Guarneri et al. · Annals of Oncology · 2016 · 225 citations · Full text

Breast Oncology, Medicine, Pathology +8

Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin‐remodelling genes as major players and a prognostic role for <i><scp>TERT</scp></i>, <i><scp>RB1</scp></i>, <i><scp>MEN1</scp></i> and <scp><i>KMT2D</i></scp>

Michele Simbolo, Andrea Mafficini, Katarzyna Sikora et al. · The Journal of Pathology · 2016 · 224 citations · Full text

Targeted Ngs, World Health Organization, Engineering +24